TY - JOUR
T1 - Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
AU - International Atherosclerosis Society/R3i Foundation Consensus Panel
AU - Fruchart, Jean Charles
AU - Santos, Raul D.
AU - Yamashita, Shizuya
AU - Libby, Peter
AU - Aikawa, Masanori
AU - Plutzky, Jorge
AU - Pradhan, Aruna
AU - Ridker, Paul
AU - Aguilar-Salinas, Carlos
AU - Al Rasadi, Khalid
AU - Amarenco, Pierre
AU - Barter, Philip J.
AU - Ceska, Richard
AU - Corsini, Alberto
AU - Ruscica, Massimiliano
AU - Després, Jean Pierre
AU - Duriez, Patrick
AU - Eckel, Robert H.
AU - Ezhov, Marat V.
AU - Farnier, Michel
AU - Ginsberg, Henry N.
AU - Hermans, Michel P.
AU - Ishibashi, Shun
AU - Karpe, Fredrik
AU - Kodama, Tatsuhiko
AU - Koenig, Wolfgang
AU - Krempf, Michel
AU - Lim, Soo
AU - Lorenzatti, Alberto J.
AU - McPherson, Ruth
AU - Nuñez-Cortes, Jesus Millan
AU - Nordestgaard, Børge G.
AU - Ogawa, Hisao
AU - Packard, Chris J.
AU - Ponte-Negretti, Carlos I.
AU - Reiner, Željko
AU - Sadikot, Shaukat
AU - Shimano, Hitoshi
AU - Sritara, Piyamitr
AU - Stock, Jane K.
AU - Su, Ta Chen
AU - Susekov, Andrey V.
AU - Tartar, André
AU - Taskinen, Marja Riitta
AU - Tenenbaum, Alexander
AU - Tokgözoğlu, Lale S.
AU - Tomlinson, Brian
AU - Tybjærg-Hansen, Anne
AU - Valensi, Paul
AU - Vrablík, Michal
N1 - Funding Information:
J-C Fruchart reports personal fees from Kowa Company ; RD Santos reports personal fees from Amgen , AstraZeneca , Merck , Akcea , Sanofi/Regeneron , Biolab , Esperion , Kowa , and Novo-Nordisk ; S Yamashita reports grants and personal fees from Kowa Company, Ltd. , Otsuka Pharmaceutical Co., Ltd. , Shionogi & Co., Ltd. , Bayer Yakuhin, Ltd. , MSD K.K., Takeda Pharmaceutical Company, Ltd. , Sanwa Kagaku Kenkyusho Co., Ltd. , Astellas Pharma Inc. , Daiichi-Sankyo Company, Ltd. , Astra Zeneka K.K., Kaken Pharmaceutical Co., Ltd. , grants from Nippon Boehringer Ingelheim Co., Ltd. , National Institute of Biomedical Innovation , Kyowa Medex Co., Ltd. , Mochida Pharmaceutical Company, Ltd. , Hayashibara Co., Ltd. , Teijin Pharma Limited and Kissei ; and personal fees from Ono Pharmaceutical Company, Ltd. , Skylight Biotec, Inc. , Pfizer , Astellas Amgen , Sanofi , and Aegerion In addition , M Yamashita has a patent PCT/JP2016/074402 (Assisting Method for the Diagnosis of Type III Hyperlipidemia) pending to Fujirebio & Osaka University, a patent PCT/JP2017/038766 (Method for Selecting Subject Needing Treatment for Dyslipidemia and Reagent for Such Selection) pending to Osaka University & Kyowa Medex Co., Ltd., and a patent PCT/JP2017/038715 (Method for Measuring Oxidized High-Density Lipoprotein) pending to Osaka University & Kyowa Medex Co., Ltd. P Libby reports a research grant from Novartis and honoraria as a scientific advisory board member for Dalcor Pharmaceuticals. He also provides unpaid consultancy for Amgen, AstraZeneca, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Pfizer, Sanofi-Regeneron, XBiotech Inc., Corvidia Therapeutics, IFM Therapeutics, Olatec Therapeutics, Medimmune and Esperion Therapeutics.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/7/1
Y1 - 2019/7/1
UR - http://www.scopus.com/inward/record.url?scp=85069746132&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069746132&partnerID=8YFLogxK
U2 - 10.1016/j.dsx.2019.05.034
DO - 10.1016/j.dsx.2019.05.034
M3 - Review article
C2 - 31405699
AN - SCOPUS:85069746132
SN - 1871-4021
VL - 13
SP - 2723
EP - 2725
JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
IS - 4
ER -
